Before joining PepGen, Dr. Kasraian served at bluebird bio, where he was instrumental in the approval and launch of three gene therapy products: SKYSONA™, ZYNTEGLO™, and LYFGENIA™.

PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological ...

Educational outreach is a cornerstone of the alliance, and the mission is to highlight and help the Magnolia State’s ...

Marks was instrumental in the rise of the CGT space ... carries a price tag of $4.25 million for the one-time treatment, while bluebird’s sickle cell therapy Lyfgenia costs $3.1 million. Prices like ...

In 1912, WC Handy published “Memphis Blues,” which, ironically, is not a blues song, but an instrumental cakewalk ... and the antecedent of BB’s sound. Bluebird, the Columbia subsidiary ...

For investors in gene therapy biotech bluebird bio, a wait-and-see approach toward a proposed acquisition has paid off. In a revised merger agreement, Carlyle and SK Capital Partners are now ...

Bluebird bio shareholders have dragged their feet in tendering shares as part of the company’s sale process, prompting buyers Carlyle and SK Capital to extend their offer deadline once again.

Blue Bird presents its propane-powered stripped chassis at the 2025 Advanced Clean Transportation (ACT) Expo. The company utilizes lightweight materials and components for its innovative ...

SOMERVILLE, Mass. (AP) — SOMERVILLE, Mass. (AP) — Bluebird Bio Inc. (BLUE) on Wednesday reported a loss of $29.1 million in its first quarter. On a per-share basis, the Somerville ...

Under the terms of the amended agreement bluebird stockholders can elect to receive either (x) the original offer of $3.00 per share in cash plus a contingent value right (“CVR”) of $6.84 per ...